Original Statistical Graphics Work

Contributing Graph Classes Using Templates

• Add a WikiWord for your class graphic in the box below and click on "Create by name."
• The template has fields, which you are free to use or to delete.
• Java script for the coding was added for coding. It will be formatted correctly if you add add your code between the

•  %CODE{lang="java"}% and %ENDCODE% 

  .

WRITE a wiki name for your class graph(s):

ARCHIVE of All WORK

Title	Contributor/Email	Reference Image	Topic Page
Profile Plot: Mean QTc by Time and Treatment	Rich Anziano (richard.anziano@pharmetheus.com) Max Cherny (Max.2.Cherny@gsk.com)		ClinECGGraph001
QT Correction Comparison	R.J. Anziano, (richard.anziano@pharmetheus.com)		ClinECGGraph002
Change from Baseline by Baseline: Categorical QTc Analysis	Rich Anziano (richard.anziano@pharmetheus.com) Max Cherny (Max.2.Cherny@gsk.com)		ClinECGGraph000
Depicting Phase 2 Efficacy Results	Mat Soukup (email: Mat.Soukup@fda.hhs.gov)		StatGraphTopic004
Forest Plot of Hazard Ratios by Patient Subgroups	Sanjay Matange (email: Sanjay.Matange@sas.com)		ClinAEGraph001
P-risk (Risk Difference) Plot of Treatment Emergent Adverse Events at PT Level	Qi Jiang (email: Qjiang@amgen.com) SAS code contributed by Haijun Ma and Jun Wei		ClinAEGraph003
Heat map	max.2.cherny@gsk.com Sanjay Matange (email: Sanjay.Matange@sas.com)		SafetyGraphicsTopic000
Dotplot of Primary SOC	Mat Soukup (email: Mat.Soukup@fda.hhs.gov) Sanjay Matange (email: Sanjay.Matange@sas.com)		StatGraphTopic005
Most Frequent On-Therapy AE Sorted by Risk Difference	FrankHarrell		ClinAEGraph000
Frequency Plot of the Change from Baseline in Alanine Aminotransferase by Visit	Robert Gordon (rgordon2@its.jnj.com)		ClinLFTGraph009
EG QTc Longitudinal Trend	jianminlong@merck.com		SafetyGraphicsTopic001
Individual QTc display	A. Paredes, Antonio.Paredes@fda.hhs.gov Max Cherny: Max2Cherny@gsk.com		ClinECGGraph003
Lab Shift Plots: Baseline versus Maximum	Susan Duke (susan.p.duke@gsk.com) Max Cherny (Max.2.Cherny@gsk.com)		ClinLFTGraph002
Time to AE Occurrence	Mat Soukup (email: Mat.Soukup@fda.hhs.gov) Max Cherny (Max.2.Cherny@gsk.com)		ClinAEGraph002
Scatter Plot of Maximum Transaminase versus Maximum Total Bilirubin	Robert Gordon (rgordon2@its.jnj.com)		ClinLFTGraph000
Cumulative Incidence for Alanine Aminotransferase (ALT): Elevations > 3 Times the Upper Limit of Normal	Robert Gordon (rgordon2@its.jnj.com)		ClinLFTGraph006
Line Plot Examples	fabrice.bancken@novartis.com<fabrice.bancken@novartis.com>;		LinePlotExamples
Liver Test Safety Panel Over Time, Baseline vs. On-study	Robert Gordon (rgordon2@its.jnj.com)		ClinLFTGraph008
Systolic Blood Pressure (Main Profiles)	Mat Soukup (email: Mat.Soukup@fda.hhs.gov)		StatGraphTopic016
Mean (and Mean Difference) of ALT (Alanine Aminotransferase) by Treatment : Profile Over Time	Robert Gordon (rgordon2@its.jnj.com)		ClinLFTGraph001
Time Course of Lab Test Values, Individual Subject	Robert Gordon (rgordon2@its.jnj.com)		ClinLFTGraph004
Liver Function Tests by Trial Day: At Risk Subjects	Robert Gordon (rgordon2@its.jnj.com)		ClinLFTGraph005
Lab Parameter Shift Plots, Baseline vs. Study	Robert Gordon (rgordon2@its.jnj.com)		ClinLFTGraph003
Distribution of Alanine Aminotransferase (ALT) by Time and Treatment	Robert Gordon (rgordon2@its.jnj.com)		ClinLFTGraph007
Boxplot of Two Treatment Groups	Mat Soukup (email: Mat.Soukup@fda.hhs.gov)		StatGraphTopic000
Summary of All EG Parameters	Mat Soukup (email: Mat.Soukup@fda.hhs.gov)		StatGraphTopic015
Sensitivity Analysis of Missing Data	Mat Soukup (email: Mat.Soukup@fda.hhs.gov)		StatGraphTopic014
Scatterplot w/ Density and Smoothed Regression	Mat Soukup (email: Mat.Soukup@fda.hhs.gov)		StatGraphTopic013
Local Reactions over Time	Mat Soukup (email: Mat.Soukup@fda.hhs.gov)		StatGraphTopic010
Reports by SOC	Mat Soukup (email: Mat.Soukup@fda.hhs.gov)		StatGraphTopic011
Scatterplot Conditioned on Race	Mat Soukup (email: Mat.Soukup@fda.hhs.gov)		StatGraphTopic012
HPA Axis Suppression	Mat Soukup (email: Mat.Soukup@fda.hhs.gov)		StatGraphTopic002
Efficacy of T4N5 The Lancet Data - Code Expands	Mat Soukup (email: Mat.Soukup@fda.hhs.gov)		StatGraphTopic009
Efficacy by Subgroup	Mat Soukup (email: Mat.Soukup@fda.hhs.gov)		StatGraphTopic008
Efficacy Across Sites	Mat Soukup (email: Mat.Soukup@fda.hhs.gov)		StatGraphTopic007
Diagnostic Plot of Linear Model	Mat Soukup (email: Mat.Soukup@fda.hhs.gov)		StatGraphTopic006
Basic Survival Plot	Mat Soukup (email: Mat.Soukup@fda.hhs.gov)		StatGraphTopic001
Data Density of Two Treatment Groups	Mat Soukup (email: Mat.Soukup@fda.hhs.gov)		StatGraphTopic003
Vital Signs: Postural Change by Time and Treatment	Rich Anziano (Richard.J.Anziano@Pfizer.com)		StatGraphTopic020
Vital Signs: Mean Change by Time and Treatment	Rich Anziano (Richard.J.Anziano@Pfizer.com)		StatGraphTopic021
Relationship Between Risk Difference and P-value for Adverse Events by Preferred Term/System Organ Class			AdverseEventsClinicalQuestionTopic009
Dotplot of Relationship between AE Proportion in Treatment v Placebo	QiJiang		AdverseEventsClinicalQuestionTopic008
Dotplot of Relationship between AE Proportion in Treatment v Placebo	QiJiang		AdverseEventsClinicalQuestionTopic007
Risk Over Time Plot for Adverse Event	QiJiang		AdverseEventsClinicalQuestionTopic006
Distribution of Days on Study to AE Onset for Subjects with AE	QiJiang		AdverseEventsClinicalQuestionTopic005
Summary of Safety Subjects Exposure by Treatment	QiJiang		AdverseEventsClinicalQuestionTopic004
Forest Plot of AE by Preferred Term	QiJiang		AdverseEventsClinicalQuestionTopic001

Original Graphics - Do you want these?

Adverse Events

General Principles and ECG/Vitals

Instructions for Contributing Vetted Graphics

Copyright © by the contributing authors. All material on this collaboration platform is the property of the contributing authors.
Ideas, requests, problems regarding Foswiki? Send feedback